HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

X-chromosomal inactivation directly influences the phenotypic manifestation of X-linked protoporphyria.

Abstract
X-linked protoporphyria (XLP), a rare erythropoietic porphyria, results from terminal exon gain-of-function mutations in the ALAS2 gene causing increased ALAS2 activity and markedly increased erythrocyte protoporphyrin levels. Patients present with severe cutaneous photosensitivity and may develop liver dysfunction. XLP was originally reported as X-linked dominant with 100% penetrance in males and females. We characterized 11 heterozygous females from six unrelated XLP families and show markedly varying phenotypic and biochemical heterogeneity, reflecting the degree of X-chromosomal inactivation of the mutant gene. ALAS2 sequencing identified the specific mutation and confirmed heterozygosity among the females. Clinical history, plasma and erythrocyte protoporphyrin levels were determined. Methylation assays of the androgen receptor and zinc-finger MYM type 3 short tandem repeat polymorphisms estimated each heterozygotes X-chromosomal inactivation pattern. Heterozygotes with equal or increased skewing, favoring expression of the wild-type allele had no clinical symptoms and only slightly increased erythrocyte protoporphyrin concentrations and/or frequency of protoporphyrin-containing peripheral blood fluorocytes. When the wild-type allele was preferentially inactivated, heterozygous females manifested the disease phenotype and had both higher erythrocyte protoporphyrin levels and circulating fluorocytes. These findings confirm that the previous dominant classification of XLP is inappropriate and genetically misleading, as the disorder is more appropriately designated XLP.
AuthorsV Brancaleoni, M Balwani, F Granata, G Graziadei, P Missineo, V Fiorentino, S Fustinoni, M D Cappellini, H Naik, R J Desnick, E Di Pierro
JournalClinical genetics (Clin Genet) Vol. 89 Issue 1 Pg. 20-6 (Jan 2016) ISSN: 1399-0004 [Electronic] Denmark
PMID25615817 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Copyright© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Chemical References
  • Nuclear Proteins
  • Porphyrins
  • Protoporphyrins
  • Receptors, Androgen
  • ZMYM3 protein, human
  • protoporphyrin IX
Topics
  • Alleles
  • Erythrocytes (metabolism)
  • Female
  • Genes, X-Linked
  • Genetic Diseases, X-Linked (diagnosis, genetics, metabolism)
  • Genotype
  • Humans
  • Male
  • Mutation
  • Nuclear Proteins (genetics)
  • Pedigree
  • Phenotype
  • Porphyrins (metabolism)
  • Protoporphyria, Erythropoietic (diagnosis, genetics, metabolism)
  • Protoporphyrins (metabolism)
  • Receptors, Androgen (genetics)
  • X Chromosome Inactivation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: